Mycorine

Miconazole Nitrate

Method of action: Gynecological Antiinfectives And Antiseptics, Stomatological Preparations

Treatment option: Pregnancy, Infection, Candidiasis,Vaginal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mycorine

What is Mycorine?

Mycorine is a topical antifungal medication formulated to treat various fungal infections of the skin. It belongs to a class of medications known as imidazoles, which work by disrupting the biological processes necessary for fungal growth and survival.

Mechanism of Action

The active therapeutic component in Mycorine interferes with the synthesis of ergosterol, a vital molecule that maintains the structural integrity of the fungal cell membrane. By inhibiting the production of this component, the medication causes the membrane to become porous and dysfunctional. This disruption leads to the leakage of essential cellular contents, effectively stopping the spread of the infection and leading to the eventual death of the fungal cells.

Common Uses

Mycorine is primarily used to manage localized skin infections caused by dermatophytes, yeasts, and other fungi. These conditions commonly include:

Tinea Pedis: Often referred to as athlete's foot, affecting the skin on the feet and between the toes.
Tinea Corporis: Also known as ringworm, characterized by red, circular skin rashes.
Tinea Cruris: Commonly called jock itch, which affects the groin and inner thigh areas.
Cutaneous Candidiasis: Skin infections caused by yeast, often occurring in warm, moist areas of the body.
Pityriasis Versicolor: A fungal infection that results in small, discolored patches of skin.

Application and Formulations

As a topical treatment, Mycorine is applied directly to the affected area of the skin. It is typically available in various formulations, such as creams, powders, or sprays, designed to ensure the active ingredient remains in contact with the infection site. This localized approach allows the medication to concentrate its effects on the fungus while minimizing systemic absorption into the rest of the body.

What side effects are possible with Mycorine?

Possible side effects and safety information

The official safety profile of Mycorine, containing Miconazole Nitrate, is organized according to the frequency and type of documented adverse reactions from government regulatory sources. These effects are classified by the physiological system they affect.

Adverse Reaction Classifications

Side effects occurring at the application site are the most frequent. For oral and buccal formulations, oral discomfort, oral pain, and dysgeusia (altered taste) are classified as Very Common (ge 10%). Common (1% to 10%) systemic effects include diarrhea, nausea, vomiting, and headache.

System-Organ Class (SOC)	Example Adverse Reaction
Skin and Subcutaneous Tissue	Burning sensation, pruritus, application site erythema.
Gastrointestinal Disorders	Upper abdominal pain, dry mouth, stomatitis.
Immune System Disorders	Hypersensitivity, Anaphylactic reaction (Rare).

Serious Safety Considerations and Restrictions

Serious Adverse Reactions are rare but include documented systemic events such as Anaphylactic Reactions, Toxic Epidermal Necrolysis (TEN), and Stevens-Johnson Syndrome (SJS).

Specific Population-Specific Constraints are documented in the labeling. The oral gel formulation is contraindicated in infants under six months or those with impaired swallowing due to the documented risk of choking/suffocation. It is also contraindicated in patients with known liver disease.

Drug Interaction Safety Notes

Due to potential systemic absorption, Miconazole carries a significant safety restriction concerning its co-administration with other medicines. The use of Mycorine with oral anticoagulants (e.g., warfarin) may lead to an enhanced anticoagulant effect, which has been associated with bleeding events, requiring official monitoring of INR (International Normalized Ratio).

Overdose and Emergency Response

The official regulatory profile for Mycorine (Miconazole Nitrate) overdose is defined by the consequences of two primary exposure scenarios: excessive topical use and accidental oral ingestion.

Documented Manifestations and Regulatory Action

In cases of excessive topical application, the documented overdose presentation is confined to localized effects on the skin, such as irritation, erythema (redness), and a burning sensation. Regulatory information states that these dermatological symptoms typically resolve upon discontinuation of the treatment.

Overdose resulting from accidental oral ingestion of the oral gel or cream is primarily associated with gastrointestinal manifestations. Officially documented symptoms include vomiting, diarrhoea, and stomach irritation. Regulatory documents do not explicitly list severe or life-threatening systemic outcomes resulting from overdose with the topical or mucosal formulations.

Emergency Response and Management

If accidental ingestion occurs, official governmental guidance mandates that an individual contact a local poison control center or emergency services immediately.

The officially designated management approach is strictly symptomatic and supportive. This is because regulatory labeling explicitly states that a specific antidote is not available for Miconazole Nitrate overdose. The procedural steps defined by regulators for managing this situation may include supportive measures carried out by medical professionals, such as administering symptomatic treatment and, in some cases, performing gastric lavage.

Therapeutic Uses of Mycorine

Mycorine (Miconazole Nitrate) is commonly used to help manage various fungal and yeast infections. It is applied across domains where additional symptomatic support is needed, primarily focusing on skin and mucosal tissues, which generally contributes to easing the overall symptom load.

Therapeutic Scope and Symptom Relief

This medicine is considered relevant for conditions characterized by periods of heightened symptoms, including common superficial fungal infections like ringworm (Tinea corporis), athlete's foot (Tinea pedis), and jock itch (Tinea cruris). It is also used in the management of mucosal yeast infections such as vulvovaginal candidiasis and oral thrush. It helps address groups of symptoms that appear or fluctuate, such as itching, redness, localized burning, and soreness.

“It helps address symptoms that interfere with daily comfort, offering supportive relief when manifestations become temporarily overwhelming.”

Practical Benefit and Clinical Contexts

Mycorine is applied in clinical settings that involve acute or unstable symptom patterns, providing symptomatic relief that helps patients cope more steadily with difficult episodes. This application assists with supporting functional stability and is relevant for easing symptoms that cluster into patterns of irregular skin discoloration and scaling associated with Pityriasis Versicolor. It is also commonly used in the management of fungal-related complications of diaper dermatitis in children.

Quick Fact: Relief for Symptomatic Itching (Pruritus)

Regulatory References

NIH MedlinePlus overview on Miconazole Topical

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Mycorine (Miconazole Nitrate) — Official Regulatory Information

Populations for whom use is contraindicated:

Individuals with known hypersensitivity or history of allergic reaction to Miconazole Nitrate, other imidazole derivatives, or any component of the specific formulation [1.1].
Infants less than 6 months of age when using the oral gel formulation, based on the potential risk of choking [1.6].

Age-Related Eligibility Rules:

Adults (18 years and older) are approved for most topical, vaginal, and oral mucosal forms.
Children 2 years of age and older are eligible for over-the-counter topical creams [2.2].
Children 12 years of age and over are approved for over-the-counter vaginal preparations [2.3].
Efficacy was not demonstrated and use is not recommended in infants less than 4 weeks of age for certain combination ointments [2.4].

Pregnancy and Lactation Eligibility Status:

Pregnancy: Miconazole is generally only recommended for use during pregnancy when necessary and when alternatives are not suitable [3.1]. Some products carry a regulatory classification of Pregnancy Category C [3.1].
Lactation: It is not known if the active component is excreted in human milk. Caution should be exercised when administered to a nursing woman [3.1].

Eligibility-Related Restrictions:

Safety and efficacy have not been established in immunocompromised patients or in very-low-birth-weight infants for specific topical combination products [2.4, 2.6].
The use of oil-based creams may reduce the effectiveness of latex contraceptives like condoms and diaphragms [1.3].

Connection to the overall eligibility profile: The official eligibility profile defines who can and cannot use Miconazole Nitrate by establishing absolute exclusions based on hypersensitivity and specific formulation risks in infants under 6 months. Eligibility is primarily granted to adults and older children, while use is restricted in specific populations, such as immunocompromised patients or those in a lactating state, where safety and efficacy data are officially not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medicine, whose active ingredient is miconazole, has the potential to interact with several other medicines. These interactions are generally pharmacokinetic, meaning the miconazole interferes with how the body processes the other drug, leading to higher levels of the co-administered drug in the bloodstream.

Key Interaction Warning

Anticoagulant Medicines (Blood Thinners): The most significant and frequently documented interaction is with warfarin and related coumarin anticoagulants (such as dicumarol and anisindione). Mycorine, even when used locally (such as an oral gel, vaginal suppository, or skin cream), can be absorbed into the body and inhibit the liver enzyme CYP2C9. This inhibition slows the breakdown of warfarin, substantially increasing its effect and leading to a significant risk of severe bleeding complications, including excessive bruising, nosebleeds, and blood in the urine. For products taken by mouth, concomitant use with warfarin is often contraindicated.

Other Potential Interactions

Mycorine can also inhibit other liver enzymes, most notably CYP3A4. This may cause increased levels and effects of other medicines that are broken down by this enzyme. Such medicines include certain immunosuppressants (like cyclosporine and tacrolimus), certain calcium channel blockers, and some opioid pain relievers.

If you are taking any prescription medicine, especially a blood thinner, you must consult your doctor or pharmacist before using any Mycorine-containing product, regardless of whether it is applied to the skin, used vaginally, or taken as an oral gel. Close monitoring of blood coagulation tests, such as the International Normalized Ratio (INR), is necessary if these medicines must be used together.

Mechanism of Action

Targeting Fungal Cell Membrane Structure

The mechanism of Miconazole Nitrate (Mycorine) primarily acts on the fungal sterol biosynthesis pathway. The drug is an inhibitor of the enzyme lanosterol 14-alpha demethylase ( CYP51), which is essential for synthesizing ergosterol. The resulting depletion of ergosterol, combined with the accumulation of toxic precursor sterols, immediately compromises the fungal cell membrane's structural integrity. This mechanistic cascade leads to a severe increase in the permeability of the fungal cell membrane.

Inducing Cellular Toxicity and Breakdown

Beyond the primary enzymatic blockade, Miconazole contributes to cellular damage through secondary effects. The molecule directly binds to phospholipids in the fungal membrane, promoting structural disruption. Concurrently, the drug inhibits fungal oxidases and peroxidases, impairing the pathogen's ability to detoxify itself. This causes an accumulation of Reactive Oxygen Species (ROS), which damages the fungal cell’s internal macromolecules and ultimately results in cellular lysis.

Dosage and Administration Information

How Mycorine is Used — Official Administration Guidelines

Mycorine, containing Miconazole Nitrate, is administered exclusively through localized routes—topical (cutaneous), intravaginal, or mucosal/buccal—depending on the specific form utilized. These administration methods and their accompanying dosing instructions are based strictly on standardized protocols.

Official Usage Patterns and Dosing

Administration Route	Standard Dosing and Frequency	Duration Principle
Topical (Skin)	Apply a thin layer twice daily (morning and evening).	Typically 2 to 4 weeks; continue for at least seven days after symptoms clear to prevent recurrence.
Intravaginal	Doses range from 100 mg to a single 1200 mg dose. Applied once daily.	Fixed courses of 1, 3, or 7 consecutive days, as specified by the regimen.
Mucosal (Buccal Tablet)	A single 50 mg tablet. Applied once daily.	Fixed course of 14 consecutive days for oropharyngeal use.

Contextual Instructions and Restrictions

Administration is governed by specific procedural conditions. Vaginal forms are consistently inserted at bedtime. The buccal tablet should be applied to the upper gum region after brushing the teeth and must be held in place with pressure for 30 seconds to ensure it adheres to the gum. For missed doses, the next scheduled application should be used; a double dose must never be taken to compensate.

Topical preparations are strictly for external use only and must not be used in the eyes, mouth, or vagina. Use is generally established for children 2 years of age and older for most skin infections; however, the buccal tablet formulation is not established for use in patients under 16 years of age.

Connection to the Overall Use Protocol

The instructions establish a structured protocol that dictates the exact method, location, and timing for administering the medication. This framework is essential as it outlines the necessary dosage forms, the fixed duration of therapy, and the required daily frequency. The procedural steps and specific administration rules collectively define the standardized approach to proper use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Mycorine

This document provides an overview of the research that has been conducted for Mycorine (Miconazole Nitrate). It describes what was studied, what patterns were reported, and what remains unclear in the evidence landscape, using strictly patient-friendly, non-advisory language.

Evidence for Use in Vaginal and Oral Yeast Infections

Research has examined Mycorine's use in conditions characterized by fluctuating or episodic manifestations, such as common vaginal and oral fungal infections. Studies monitored outcomes related to physical discomfort and physiological imbalance, exploring how symptoms change over defined time intervals.

Research on Vaginal Yeast Infections (VVC)

Mycorine was studied for vaginal yeast infections, with research primarily consisting of randomized controlled trials (RCTs) and systematic reviews. Researchers examined three key outcomes: a combined measure of outcome (combining clinical and microbiological status), mycological status, and the reported changes in symptoms like itching and burning. Studies evaluated adult women diagnosed with uncomplicated VVC, and specific research also included populations with underlying conditions, such as diabetes.

Findings describe patterns observed in the studies, reporting varying measurements of mycological status and symptom changes across different short-term regimens. The relationship between the dosage form (e.g., cream versus suppository) and the final measured outcome is not consistently characterized across all published trials.

Research on Oral Thrush (Oropharyngeal Candidiasis)

Mycorine was evaluated in trials comparing it to other common treatments for oral thrush. Research examined outcomes related to physical discomfort, such as the reported changes in visible mucosal lesions and microbiological status. Studies monitored various populations, including adults (some who were immunocompromised), infants, and the elderly. Comparative evidence is limited against some of the newest antifungal agents developed for oral candidiasis.

Evidence for Use in Common Skin Fungal Infections

Research has explored Mycorine for common skin fungal infections, including dermatophytoses and Pityriasis Versicolor, examining outcomes linked to inflammatory or irritative states. Key outcomes assessed included clinical status (reported changes in physical signs like scaling) and mycological status (negative lab test results).

Long-Term Studies and Follow-up Assessments

The research exploring short-term symptom changes primarily involves studies where the follow-up durations were limited. The core evidence base includes research into short-term changes, but less information is available on sustained patterns. Long-term effects are not fully established regarding the durability of response or the frequency of recurrence over many months or years.

What is Still Uncertain About Mycorine Research

Research highlights what is known — and what is still uncertain — in the evidence landscape. Findings were mixed in some comparative trials, meaning that certainty remains low in areas such as head-to-head comparison against newer therapeutic options. Research for certain non-albicans fungal species is more limited than for the primary causes of infection.

Key Studies & References Miconazole Topical: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Mycorine (FAQ)

Q: How quickly does Mycorine typically start to have an effect?

The medicine is studied based on the time required to complete the treatment course, which is essential for achieving a sustained resolution. Regulatory documents establish the full course of treatment as lasting a specific, fixed duration, typically between one to four weeks. Studies have examined how symptoms change over defined short time intervals during this treatment period.

Q: Is it normal to feel a change in symptoms within the first week of using Mycorine?

Research has focused on monitoring outcomes related to reported changes in symptoms and physical discomfort during short-term treatment intervals. While symptom changes may be observed, the duration of therapy is established to meet the requirements of the treatment protocol.

Q: What is the expected length of time someone takes Mycorine?

The length of time Mycorine is used is fixed and depends on the specific formulation being used (such as cream, gel, or suppository). Official courses typically range from a single day up to 14 consecutive days for mucosal use, and up to four weeks for topical skin infections. This set duration is established in the product's official instructions.

Q: Are there any common side effects people report when starting Mycorine?

The official safety profile documents several effects as Very Common or Common, which means they are reported by many users. These often occur at the start of treatment and include application site reactions, oral discomfort, headache, nausea, and vomiting. A complete list of documented effects is available in the dedicated side effects section.

Q: What are the general rules for stopping Mycorine?

The official instructions indicate that for certain forms, particularly topical use, treatment should continue for a specified number of days, often for at least seven days after symptoms have cleared. This guidance reflects the structured protocol for completing the treatment course. The exact length is specified in the full regimen.

Q: Is it necessary to have routine blood work done while taking Mycorine?

Official documentation specifies that close monitoring of blood coagulation tests, such as the International Normalized Ratio (INR), is necessary only when Mycorine is used concomitantly with oral anticoagulant medicines, such as warfarin. This ensures detection of a potential drug effect in that specific scenario.

Q: How long after stopping Mycorine can I safely use an interacting medicine?

The time it takes for a medicine to leave the body is related to its half-life. Official information reports that the oral formulation of the active ingredient, miconazole, has a biological half-life of approximately 24 hours. Healthcare providers use this type of pharmacokinetic data to determine the appropriate timing for using other medicines.

Q: What should I do if I suspect an interaction between Mycorine and another drug?

Official documentation includes a statement that individuals taking prescription medicines should consult their healthcare provider or pharmacist before using any Mycorine-containing product. This ensures that any potential risks can be evaluated by a healthcare professional.

Q: Is Mycorine available in multiple dosage forms (e.g., tablet, capsule)?

The active ingredient is formulated into various preparations for different administration routes. These forms include a topical cream, ointment, powder, vaginal suppository, oral gel, and a buccal tablet formulation. The specific form chosen is based on the site of the infection being treated.

Q: Does Mycorine cause long-term side effects that I should know about?

Research has primarily focused on studies that explored short-term changes and symptom relief over fixed treatment periods. Official research overviews indicate that information regarding the long-term effects of Mycorine, such as the durability of response or frequency of recurrence over many months or years, is not fully established.

Q: Can Mycorine affect my ability to drive or operate machinery?

For some formulations, official product information indicates that the medicine is not expected to affect alertness or the ability to drive or operate machinery. However, the official label advises that patients should consider how they feel before engaging in these activities.

Q: Can Mycorine be used by people with kidney problems?

Official information indicates that based on the medicine's localized administration and very low systemic absorption, the need for dosage adjustment related to kidney function is not highlighted in the product labeling. However, specific studies in patients with impaired renal function have not been performed.

Q: Is Mycorine known to interact with birth control pills?

Mycorine is known to interfere with the liver enzyme CYP3A4, which is involved in processing certain other medicines, including components of some birth control pills. This enzyme interference mechanism is a factual description of how the drug can affect the body's processing of co-administered medicines.

Q: Where can I find published information about the effectiveness of Mycorine?

Factual information on the effectiveness, research themes, and safety for Mycorine is published and maintained by government regulatory and public health authorities. These sources include the NIH (MedlinePlus), the FDA, the EMA, and other national health agencies in their official prescribing documents.

Q: Is there any public data on how Mycorine was studied in diverse patient populations?

Official research overviews describe that studies have evaluated various populations, which may include adult women with uncomplicated infections, adults who were immunocompromised, infants, and the elderly across different formulations. This is done to establish the medicine’s effectiveness and safety profile in different groups.

Q: Is it possible for Mycorine to affect blood test results?

The use of Mycorine with oral anticoagulant medicines requires monitoring of the blood coagulation test known as the International Normalized Ratio (INR). This indicates the medicine’s potential for impacting these specific blood measurements when the two drugs are used together.

Q: Is it possible to have an allergic reaction to the non-active ingredients in Mycorine?

Official contraindications for the medicine include individuals with a known history of hypersensitivity or allergic reaction to the active ingredient (Miconazole Nitrate), other imidazole derivatives, or any other component of the specific formulation being used. This information is outlined in the official prescribing information regarding hypersensitivity.

Q: Are there any specific lifestyle changes that are often discussed alongside Mycorine use?

Official eligibility information describes a specific restriction regarding certain formulations. The use of oil-based vaginal creams may reduce the effectiveness of latex contraceptives, such as condoms and diaphragms, as noted in the regulatory documents.

Q: Is the long-term use of Mycorine supported by current research?

The core evidence base includes research into short-term changes and duration of response over fixed treatment courses. Official research documents state that long-term effects regarding the durability of response or the frequency of recurrence over many months or years are not fully established.

How should Mycorine be stored and disposed of?

Official Storage and Disposal Instructions

Mycorine (Miconazole Nitrate) must be stored and handled according to specific regulatory requirements to ensure stability and safety.

Storage Condition	Requirement
Temperature	Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Do not freeze.
Protection	Store in the original, tightly closed container, protected from light and moisture.
Child Safety	Keep the medicine out of the reach and sight of children.
Disposal	Dispose of unused or expired product according to local, regional, and national regulations. The product must not be discarded into sewage systems or water courses.